Evidence map›Paper›PMID 42714132›Full record

ArticleJournal of clinical microbiology2026

Benchmarking four commercial antimicrobial susceptibility testing systems and disk diffusion to reference broth microdilution in the assessment of gram-negative bacterial isolates.

Daniel D Rhoads, Jingzi Sherman, Felicia Chen, Kristin Baker, Karissa Culbreath, Erin McElvania, Amanda Harrington, Vincent Streva, Jamie Marino, Lars F Westblade and 2 more

Abstract readComparative StudyEvaluation Study
In one paragraph

Article in Journal of clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Daniel D RhoadsPathology & Laboratory Medicine Department, Cleveland Clinic, Cleveland, Ohio, USA.ORCID 0000-0002-7636-5191
Jingzi ShermanSelux Diagnostics, Charlestown, Massachusetts, USA.ORCID 0009-0001-5569-0825
Felicia ChenSelux Diagnostics, Charlestown, Massachusetts, USA.
Kristin BakerSelux Diagnostics, Charlestown, Massachusetts, USA.
Karissa CulbreathDepartment of Infectious Disease, Tricore Laboratories, Albuquerque, New Mexico, USA.ORCID 0000-0003-2363-1553
Erin McElvaniaDepartment of Pathology, University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA.ORCID 0009-0007-3959-2583
Amanda HarringtonDepartment of Pathology and Laboratory Medicine, Loyola University, Chicago, Illinois, USA.
Vincent StrevaDivision of Infectious Disease Diagnostics, Northwell Health Laboratories, New York, New York, USA.ORCID 0009-0004-6306-7517
Jamie MarinoDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA.ORCID 0009-0006-5604-7117
Lars F WestbladeDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA.ORCID 0000-0003-3079-7674
Eric SternSelux Diagnostics, Charlestown, Massachusetts, USA.ORCID 0000-0001-9039-3693
Patricia J SimnerDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6134-151X

Funding

Next-generation phenotypic antimicrobial susceptibility test platform: rapid resultsand comprehensive menusSB1AI136125 · NIAID · SELUX DIAGNOSTICS, INC. · PI STERN, ERIC · 2021 to 2023
$2.8M
NIAID NIH HHS SB1 AI136125Selux
6 · The paper itself

Abstract

Commercial antimicrobial susceptibility testing (AST) systems for gram-negative bacteria provide operational advantages over reference broth microdilution (BMD) testing, but the results produced by commercial AST systems might not be as accurate as the reference method. Assessing and comparing the performance of AST systems can be informative for clinical microbiology practice. In total, 280 clinical isolates and 100 isolates from the U.S. Centers for Disease Control and Prevention Antimicrobial Resistance Isolate Bank, including Enterobacterales and

Indexed as

Anti-Bacterial AgentsGram-Negative BacteriaBenchmarkingGram-Negative Bacterial InfectionsHumansMicrobial Sensitivity TestsPseudomonas aeruginosaUnited StatesAnti-Bacterial Agentsantibiotic susceptibility testingantimicrobial resistance

Identifiers

PMID42714132
PMCPMC13650682

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.